Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency

J Pediatr. 1991 Jul;119(1 Pt 1):29-34. doi: 10.1016/s0022-3476(05)81034-0.

Abstract

Ten prepubertal children with stature at or below the 1st percentile for height and without growth hormone deficiency received 0.3 U recombinant growth hormone per kilogram daily for 2 years before puberty. Their growth velocity increased from 4 +/- 0.3 cm/yr before treatment to 10.7 +/- 0.6 and 8.8 +/- 0.6 cm, respectively, during the first and second years of treatment, and then remained at 5.7 +/- 0.7 cm the year after the end of growth hormone administration. This resulted in a near normalization of adolescent height. Bone maturation paralleled chronologic age, and therefore the expected final height of the children increased by approximately 10 cm. Administration of growth hormone induced a reversible hyperinsulinemia, with moderate and transient changes in glucose metabolism. A prospective, randomized study, including an untreated cohort, will be needed to confirm the effects on final height and to determine the magnitude of the response in familial short stature.

MeSH terms

  • Adolescent
  • Blood Glucose / analysis
  • Body Height
  • Child
  • Feasibility Studies
  • Female
  • Growth Disorders / blood
  • Growth Disorders / drug therapy*
  • Growth Hormone / administration & dosage
  • Growth Hormone / therapeutic use*
  • Humans
  • Insulin / blood
  • Insulin-Like Growth Factor I / analysis
  • Male
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use

Substances

  • Blood Glucose
  • Insulin
  • Recombinant Proteins
  • Insulin-Like Growth Factor I
  • Growth Hormone